
TO STUDY THE EFFECT OF ADDITION OF NALBUPHINE TO INTRATHECAL BUPIVACAINE USED FOR ELDERLY PATIENT IN LOWER ABDOMINAL SURGERIES UNDER SPINAL ANAESTHESIA: A RANDOMISED DOUBLE BLINDED CONTROL STUDYRashmi Dubey¹, Swati Bisht²**HOW TO CITE THIS ARTICLE:**

Rashmi Dubey, Swati Bisht. "To Study the Effect of Addition of Nalbuphine to Intrathecal Bupivacaine used for Elderly Patient in Lower Abdominal Surgeries Under Spinal Anesthesia: A Randomized Double Blinded Control Study". *Journal of Evolution of Medical and Dental Sciences* 2014; Vol. 3, Issue 70, December 15; Page: 14963-14970, DOI: 10.14260/jemds/2014/4012

ABSTRACT: BACKGROUND AND OBJECTIVES: The purpose of this study was: 1. To assess, evaluate and compare the analgesic effect of intrathecal nalbuphine when added to hyperbaric intrathecal bupivacaine and bupivacaine alone. 2. To evaluate the onset, quality and duration of sensory and motor blockade achieved with hyperbaric bupivacaine and nalbuphine combination when administered intrathecally for spinal anesthesia in lower abdominal surgery. 3. To study the effect of intrathecal nalbuphine on vital parameters. 4. To study any side effects and complication.

METHODOLOGY: 40 ASA I and II patients of age group 50-70 years, scheduled for below umbilicus surgeries were chosen for this study. Patients were randomized in two equal groups of 20 each by lottery method. Group I (Study Group) received 3 ml of hyperbaric bupivacaine 0.5 % + 0.5 ml inj. nalbuphine (0.5 mg) intrathecally. Group II (Control Group) received 3 ml of hyperbaric bupivacaine 0.5 % + 0.5 ml of inj. normal saline intrathecally. Assessment of motor and sensory blockade was done by Bromage scale and pin prick method. Pulse rate, BP, respiratory rate and SpO₂ were monitored throughout intraoperative period and 24hrs postoperative period. **RESULTS:** There is no significant difference between 2 groups for onset of motor and sensory blockade but mean time of postoperative analgesia in Study Group was highly significant than Control Group. No patient in our study developed any side effects. **CONCLUSION:** Nalbuphine provides better quality of block as compared to bupivacaine alone. It also prolongs postoperative analgesia when used as adjuvant to spinal bupivacaine in elderly patients.

KEYWORDS: Spinal anaesthesia, Nalbuphine, Postoperative analgesia, Bupivacaine, Intrathecal.

INTRODUCTION: Spinal anaesthesia is now 100 years young and still the most popular regional anaesthesia technique. However the drug used for spinal anaesthesia doesn't have the advantage of post-operative analgesia. It is a challenge for anaesthesiologist as management of pain is his domain in the perioperative period. Many drugs have been used intrathecally as an adjuvant to local anaesthetic to prolong post-operative pain relief but have their own adverse effects. Nalbuphine is an opioid which is structurally related to oxymorphone. It is an opioid agonist antagonist with agonist action at kappa and antagonist action at mu receptors.^{1,2} Nalbuphine and other kappa agonists had provided reasonably potent analgesia in certain models of visceral nociception.³ Nalbuphine being an agonist antagonist is less likely to cause side effects like pruritus, respiratory depression, urinary retention, excessive sedation etc because of its action at kappa receptors. Previous studies have shown that epidural or intrathecal administration of nalbuphine produces a significant analgesia accompanied by minimal pruritus and respiratory depression.^{4,5} Culebras et al. in 2002 used

ORIGINAL ARTICLE

intrathecal nalbuphine in doses of 0.2, 0.8 and 1.6 mg with 10 mg of 0.5% hyperbaric bupivacaine in patients undergoing cesarean section under subarachnoid block (SAB) and found 0.8 mg of nalbuphine as an effective dose.⁶

In search of an ideal agent we have studied the effect of nalbuphine added as an adjuvant to bupivacaine & compare it with effect of plain bupivacaine for post-operative analgesia and quality of block.

MATERIALS AND METHODS: After approval from institutional ethical committee and written informed consent 40 patients of both genders ASA I & ASA II between ages 50-70 yrs posted for below umbilical lower abdominal surgeries were selected for the purpose of this study. Pre-anesthetic checkup was done. Patients with contraindication to spinal anaesthesia were excluded from the study. Patients kept NBM for 6-8 hours. Randomization was done into two groups by lottery method.

Group I (Study group): Inj. Bupivacaine (0.5%) 3 ml + Inj. Nalbuphine (0.5mg) 0.5 ml intrathecally.

Group II (Control group): Inj. Bupivacaine (0.5%) 3 ml + Inj. Normal Saline 0.5 ml intrathecally.

Sedatives and hypnotics were avoided in pre, intra and post-operative period. IV line was secured with 20 G IV cannula. All patients were preloaded with Ringer lactate solution @ 10 ml/kg. Monitors were attached before performing the procedure (Pulse Oxymeter, NIBP, ECG). The study medication was prepared by the person who is not involved in the study to ensure blinding of the anaesthetist. Under all aseptic precautions, subarachnoid block was given using 26 G Quinke's Spinal Needle in sitting position. Respective agents were injected according to the group. The assessments of the haemodynamic parameters were noted. Onset of sensory block was judged by pin prick method and motor blockade was judged with Bromage scale.

BROMAGE SCALE:

SCORE	CRITERIA
1.	Complete block (unable to move feet or knee).
2.	Almost complete block (able to move feet only).
3.	Partial block (just able to move knees).
4.	Detectable weakness of hip flexion while supine position.
5.	No detectable weakness of hip flexion while supine.
6.	Able to perform partial knee bend.

Height of sensory block was achieved up to T6 level.

Following parameters were observed: Time of onset of sensory blockade (T1), Time of onset of motor blockade (T2), Time of peak sensory blockade (T3), Time of peak motor blockade (T4), duration of post-operative analgesia (T5).

Fall in MAP > 20 % of basal value was treated with Inj. Mepheteramine. Bradycardia i.e. HR > 15-20 % fall form basal value was treated with Inj. Atropine. Rescue analgesia with Inj. Tramadol 100 mg or Inj. Diclofenac 75 mg IM was given. Vital parameters were monitored every 5 min for 20 min

ORIGINAL ARTICLE

then 10 min till end of surgery. Peri operatively patients were observed carefully for next 24hrs for the side effects like respiratory depression, nausea, vomiting, itching etc. Data was expressed as Mean \pm SD. ANOVA test was used for comparative analysis. P value <0.05 was considered as significant.

RESULTS: Demographic profile for all patients in group is present in figure no. 1, 2 and 3. There was no statistically significant difference between two groups with respect to age, sex and ASA grading.




Figure 1




Figure 2




Figure 3

Mean onset of sensory blockade in nalbuphine group was 58 sec and in control group was 60 sec. p value is > 0.05 showing that there no statistically significant difference between two groups (Figure 4).




Figure 4

ORIGINAL ARTICLE

Mean onset of motor blockade in nalbuphine group was 110 sec and in control group was 110 sec. p value is > 0.05 showing that there no statistically significant difference between two groups (Figure 5).




Figure 5

Time of peak sensory block in nalbuphine group was 380 sec and in control group was 380 sec. p value is > 0.05 showing that there no statistically significant difference between two groups (Figure 6).




Figure 6

Time of peak motor block in nalbuphine group was 210sec and in control group was 220 sec. p value is > 0.05 showing that there no statistically significant difference between two groups (Figure 7).




Figure 7

ORIGINAL ARTICLE

Duration of post-operative analgesia i.e. time between drug administration and request of first analgesic. In nalbuphine group duration of post-operative analgesia was 8 to 9hours (566+/- 15.5min.) and in control group was 2 to 3 hours (159.5 +/- 18.42min.).p value is 0.000 which was highly significant statistically (Figure 8, Table 1).




Figure 8

PARAMETER	GROUP I AM + SD	GROUP II AM + SD	P VALUE	SIGNIFICANCE
Duration of analgesia	516 + 15.5	159.5 + 18.42	0.000	HIGHLY SIGNIFICANT

Table 1: Duration of Analgesia

There was statistically significant difference in haemodynamic parameters like heart rate, mean, systolic and diastolic BP but clinically these parameters were within normal limits and did not required any intervention (Table 2).

Parameters	Group I (n= 20) (Mean ± SD)	Group II (n=20) (Mean ± SD)	p-value
HR	85.14 ± 10.75	75.7 ± 7.8	>0.001
SBP	126.86 ± 11.25	110 ± 2.4	
DBP	74 ± 7.66	65.1 ± 5.3	

Table 2: Comparison of Vital Parameters

*significant

Respiratory rate and SPO2 were almost similar in both the groups. There was no side effects intra operatively and postoperatively in our study.

DISCUSSION: Subarachnoid block is technique of choice for lower abdominal and lower extremity surgeries. Since subarachnoid block with bupivacaine has post-operative analgesia for short period. Many adjuvants like fentanyl, morphine, buprenorphine, midazolam, clonidine have been used in past to prolong postoperative analgesia but having their own side effects.

ORIGINAL ARTICLE

In present study we have used bupivacaine with nalbuphine as an adjuvant to see the duration of analgesia post operatively and any side effects. After subarachnoid block was given there is no significant difference between onset of sensory and motor block in both the groups.

There is also no significant difference between peak sensory and motor block in both the groups but duration of post-operative analgesia in study group with added adjuvant nalbuphine was 8-9 hours and in control group with plain bupivacaine was 2-3 hours.

Nalbuphine is a synthetic opioid with mu agonist and antagonist properties. Mechanism of analgesia by its agonistic action. nalbuphine stimulates kappa receptor. This inhibits release of neurotransmitter that mediates pain such as substance P. In addition it acts as post synaptic inhibitor on the interneuron and output neuron of spinothalamic tract which transports nociceptive information.^{7,8} In the nalbuphine group, almost 25% of elderly patients were controlled hypertensive. However no cardio pulmonary adverse effects were seen. It improves quality of block and prolonged and long lasting post-operative analgesia. No adverse effects like other opioids (respiratory depression, nausea, vomiting, and pruritus). It is also cost effective. Nalbuphine given systemically has a reduced incidence of respiratory depression and has been used to antagonize the side-effects of spinal opiates. There are a few studies of neuraxial administration of nalbuphine that have shown to produce a significant analgesia accompanied by minimal pruritus and respiratory depression.

A study comparing the different doses of nalbuphine was by Culebras et al., who studied intrathecal nalbuphine in doses of 0.2, 0.8 and 1.6 mg in 90 obstetric patients undergoing caesarean section and found 0.8 mg as the most effective dosage.⁹ Lin et al. found that the addition of intrathecal nalbuphine 0.4 mg to hyperbaric tetracaine, compared with intrathecal morphine 0.4 mg for SAB, improved the quality of intraoperative and postoperative analgesia, with fewer side-effects.¹⁰ In another study on 60 obstetric patients scheduled for caesarean section under SAB morphine 0.1 mg or nalbuphine 1 mg or morphine 0.1 mg with nalbuphine 1 mg in addition to 0.5% bupivacaine 10 mg was used and it was concluded that effective analgesia was prolonged in the morphine group and morphine with nalbuphine group, but the incidence of pruritus was significantly lower in the nalbuphine group, while the incidence of nausea and vomiting did not differ in the different groups.¹¹ In 2011 study by Tiwari and Tomar showed that nalbuphine hydrochloride (400 µg) significantly prolongs the duration of sensory blockade and postoperative analgesia without any side effect or complication when introduced intrathecally along with hyperbaric bupivacaine.¹² A similar study showed that two-segment regression time of sensory blockade and duration of effective analgesia was prolonged in patients receiving 0.4 mg and 0.8 mg nalbuphine ($P < 0.05$), and the incidence of side-effects was significantly higher in the latter group ($P < 0.05$). The authors concluded that nalbuphine used intrathecally was a useful adjuvant in SAB and, in a dose of 0.4 mg, prolonged postoperative analgesia without increased side-effects.^{13,14} Schimitz et al studied effect of intrathecal opioid medication for perioperative analgesia in handicapped children.¹⁵ There are some studies about use of intrathecal and intravenous opioids for pain relief.^{16,17} Another study compares intrathecal morphine with intrathecal nalbuphine in children.¹⁸

Neuraxial use of nalbuphine is in modern anesthesia practice for more than 10 years. We are not aware of any reports of neurotoxicity of intrathecal nalbuphine since then. Some of the previous studies were even conducted with intrathecal nalbuphine in pregnant patients, but no neurotoxicity was reported in them.^{9,12,19,20} The FDA in 2005 advised that nalbuphine may be used during labor and delivery only if clearly indicated and if the potential benefits outweigh the risks. We are unaware of

ORIGINAL ARTICLE

any definite caution in the use of nalbuphine by any statutory authority in non-pregnant patients and in subjects more than 18 years old. We included only middle to old aged patients in our study and obtained clearance from the local institutional ethical committee.

CONCLUSION: Nalbuphine provides better quality of block as compared to bupivacaine alone. It also provides post-operative analgesia for almost 8-9 hours when used as an adjuvant to bupivacaine. From present study, we feel that addition of nalbuphine to bupivacaine is an effective measure of providing post-operative analgesia without any adverse effects for patients undergoing infra-umbilical surgeries under Sub arachnoid Block.

REFERENCES:

1. Zarr GD, Werling LL, Brown SR, Cox BM. Opioid ligand binding sites in the spinal cord of the guinea-pig. *Neuropharmacology* 1986; 25: 47-80. [PubMed]
2. De Souza EB, Schmidt WK, Kuhar MJ. Nalbuphine: An autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. *J Pharmacol Exp Ther* 1988; 244: 391-402. [PubMed]
3. Schmauss C, Doherty C, Yaksh TL. The analgesic effects of an intrathecally administered partial opiate agonist, nalbuphine hydrochloride. *Eur J Pharmacol* 1982; 86: 1-7. [PubMed]
4. Lin ML. The analgesic effect of subarachnoid administration of tetracaine combined with low dose of morphine or nalbuphine for spinal anesthesia. *Ma Zui Xue Za Zhi* 1992; 30: 101-5. [PubMed]
5. Fournier R, Gamulin Z, Macksay M, Van Gessel E. Intrathecal morphine versus nalbuphine for post-operative pain relief after total hip replacement. *Anesthesiology* 1998; 89: 867. [PubMed]
6. Culebras X, Gaggero G, Zatloukal J, Kern C, Marti RA. Advantages of Intrathecal nalbuphine, compared with intrathecal morphine, after Cesarean delivery: An evaluation of postoperative analgesia and adverse effects. *Anesth Analg* 2000; 91 (3): 601-5. [PubMed] [Full Free Text]
7. Stanley F Malamed. *Neurophysiology in Hand book of local anesthesia* 2nd Edition, Jaypee brothers: 1986: 20.
8. Ready BL Acute perioperative pain. In Miller RD. *Anaesthesia* 5th Edition, Churchill Livingstone, Philadelphia, 2000: 2323: 50.
9. Mikuni I, Hirai H, Toyama Y, Takahata O, Iwasaki H. Efficacy of intrathecal morphine with epidural ropivacaine infusion for postcesarean analgesia. *J Clin Anesth.* 2010 Jun; 22 (4): 268-73.
10. Fournier R, Van Gessel E, Macksay M, Gamulin Z. Onset and offset of intrathecal morphine versus nalbuphine for postoperative pain relief after total hip replacement. *Acta Anaesthesiol Scand.* 2000 Sep; 44 (8): 940-5. [PubMed]
11. Yoon JY, Jee YS, Hong JY. A Comparison of Analgesic Effects and side effects of intrathecal morphine, nalbuphine and morphine-nalbuphine mixture for pain relief during a caesarean section. *Korean J Anaesthesiol* 2002; 42: 627-33. [KOMCI]
12. Tiwari AK, Tomar GS, Agrawal J. Intrathecal Bupivacaine in Comparison With a Combination of Nalbuphine and Bupivacaine for Subarachnoid Block: A Randomized Prospective Double-Blind Clinical Study. *Am J Ther.* 2011, Sep 8 [Epub ahead of print] [PubMed].

ORIGINAL ARTICLE

13. Yang T, Breen TW, Archer D, Fick G. Comparison of 0.25 mg and 0.1 mg intrathecal morphine for analgesia after cesarean section. *Can J Anaesth* 1999; 46: 856-60. [PubMed]
14. Mukherjee A, Pal A, Agrawal J, Mehrotra A, Dawar N. Intrathecal nalbuphine as an adjuvant to subarachnoid block: What is the most effective dose?. *Anesth Essays Res* 2011;5:171-5 [Publisher website] [Free Full Text]
15. Schmitz A, Salgo B, Weiss M, Dillier CM, Frotzler A, Gerber AC. Intrathecal opioid medication for perioperative analgesia in severely handicapped children undergoing spinal operations. *Anaesthesist*. 2010 Jul; 59 (7): 614-20. doi: 10.1007/s00101-010-1733-7. [PubMed]
16. Sarantopoulos C. Intravenous lidocaine and intrathecal opioids. *Anesth Analg*. 2000 Oct; 91 (4): 1042. [PubMed]
17. Sarantopoulos C, Fassoulaki A. Systemic opioids enhance the spread of sensory analgesia produced by intrathecal lidocaine. *Anesth Analg*. 1994 Jul; 79 (1): 94-7. [PubMed] [Free Full Text]
18. Krechel SW, Helikson MA, Kittle D, Eggers GW Jr. Intrathecal morphine (ITM) for postoperative pain control in children: a comparison with nalbuphine patient controlled analgesia (PCA). *Paediatr Anaesth*. 1995; 5 (3): 177-83. [PubMed]
19. Yaksh T, Birnbach DJ. Intrathecal nalbuphine after cesarean delivery: are we ready? *Anesth Analg*. 2000 Sep; 91 (3): 505-8. [PubMed] [Free Full Text]
20. Rust LA, Waring RW, Hall GL, Nelson EI. Intrathecal narcotics for obstetric analgesia in a community hospital. *Am J Obstet Gynecol*. 1994 Jun; 170 (6): 1643-6; discussion 1646-8. [PubMed]

AUTHORS:

1. Rashmi Dubey
2. Swati Bisht

PARTICULARS OF CONTRIBUTORS:

1. Associate Professor, Department of Anaesthesiology, VIMS and RC, Bangalore.
2. Associate Professor, Department of Anaesthesiology, VIMS and RC, Bangalore.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Rashmi Dubey,
Flat No. 205, Shri Vandana Regency,
Gulmohar Enclave Road,
Kundalhalli Gate, Marthalli Post,
Bangalore.
Email: drrashmi1993@gmail.com

Date of Submission: 11/11/2014.
Date of Peer Review: 12/11/2014.
Date of Acceptance: 08/12/2014.
Date of Publishing: 13/12/2014.